Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merrimack Pharmaceuticals Inc (MACK)

Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 168.00 (-0.81%)
NYT : 41.61 (-1.37%)
ONCY : 1.0400 (-3.70%)
ONC.TO : 1.44 (-2.04%)
MACK : 14.68 (unch)
INCY : 52.72 (-0.94%)
MRTX : 58.70 (-0.17%)
BNTX : 86.40 (+0.07%)
Pancreatic Cancer Battle Boosted by $200M VC Firm

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

ONC.TO : 1.44 (-2.04%)
ONCY : 1.0400 (-3.70%)
MACK : 14.68 (unch)
INCY : 52.72 (-0.94%)
MRTX : 58.70 (-0.17%)
BNTX : 86.40 (+0.07%)
Pancreatic Cancer Battle Boosted by $200M VC Firm

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

AAPL : 168.00 (-0.81%)
ONCY : 1.0400 (-3.70%)
ONC.TO : 1.44 (-2.04%)
MACK : 14.68 (unch)
INCY : 52.72 (-0.94%)
MRTX : 58.70 (-0.17%)
BNTX : 86.40 (+0.07%)
Merrimack Reports First Quarter 2023 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023.

MACK : 14.68 (unch)
Merrimack Reports Full Year 2022 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022.

MACK : 14.68 (unch)
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss...

MACK : 14.68 (unch)
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen

Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.

MRNA : 103.44 (-0.34%)
SGEN : 228.74 (-0.07%)
MACK : 14.68 (unch)
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.

MRNA : 103.44 (-0.34%)
SGEN : 228.74 (-0.07%)
MACK : 14.68 (unch)
BCLI : 0.5408 (+2.60%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...

ONCY : 1.0400 (-3.70%)
ONC.TO : 1.44 (-2.04%)
SGEN : 228.74 (-0.07%)
MRTX : 58.70 (-0.17%)
AMGN : 264.07 (-0.59%)
MACK : 14.68 (unch)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French...

ONCY : 1.0400 (-3.70%)
ONC.TO : 1.44 (-2.04%)
SGEN : 228.74 (-0.07%)
MRTX : 58.70 (-0.17%)
AMGN : 264.07 (-0.59%)
MACK : 14.68 (unch)

Barchart Exclusives

Stocks Rise Before the Open With Earnings in Focus, U.S. Economic Data and Fed Speak on Tap
June S&P 500 E-Mini futures (ESM24) are up +0.12%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.27% this morning as investors awaited a new round of U.S. economic data, comments from Federal Reserve officials, as well as corporate earnings reports, with the spotlight on results from streaming giant Netflix. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar